Study of OMNI Surgical System and iStent for Eyes With OAG (Trident)

Sight Sciences

Status: Terminated

Conditions: Glaucoma, Open-Angle

Treatments: Device: iStent inject; Device: Canaloplasty; Device: Canaloplasty and trabeculotomy with the OMNI system.

Study type: Interventional

Funder types: Industry

Identifiers

NCT04658095

07062

Details and patient eligibility

About

First, to compare safety and effectiveness outcomes for canaloplasty and trabeculotomy using the OMNI Surgical System to implantation of the iStent inject in lowering intraocular pressure (IOP) in pseudophakic eyes with open angle glaucoma (OAG), and second, to compare safety and effectiveness outcomes for canaloplasty alone (using the OMNI Surgical System)to implantation of the iStent Inject in lowering IOP in pseudophakic eyes with OAG.

Full description

A multicenter, prospective, parallel group study planned to randomize 459 subjects to either 1)canaloplasty + trabeculotomy with the OMNI, 2)canaloplasty alone with the OMNI, or 3)iStent inject in an equal allocation ratio (1:1:1); The study includes baseline and terminal (Month 12) washout. Up to 26 centers in the UK and EU were planned to participate.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male or female subjects, 18 years or older
2. Pseudophakic
3. Diagnosis of open angle glaucoma (OAG)
4. On 1-5 ocular hypotensive medications

Exclusion criteria

1. Any of the following prior treatments for glaucoma:

   • Suprachoroidal stent (e.g. Cypass, iStent Supra)
   • Laser trabeculoplasty ≤ 8 weeks prior to Baseline visit with a MIGS or other glaucoma device including but not limited to iStent, iStent inject, Hydrus, CyPass
   • Trabeculectomy or other bleb forming procedure including Xen, PreserFlo, Express, glaucoma draining device/valve
   • Prior canaloplasty, goniotomy, or trabeculotomy including procedures with GATT, Kahook Dual Blade, iTrack, Trabectome
   • Ciliary ablation procedures including Endocyclophotocoagulation (ECP), Cyclophotocoagulation (G probe), Micropulse laser, or high intensity focused ultrasound (HIFU)

2. Any other form of glaucoma other than OAG

3. Concurrent ocular pathology or systemic medical condition which, in the Investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, active intraocular infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere with compliance to elements of the study protocol (e.g., returning to investigator's office for follow-up visits).

4. Women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

10 participants in 3 patient groups

Ab-interno canaloplasty and trabeculotomy using the OMNI Surgical System

Active Comparator group

Description:

Sequential canaloplasty (up to 360 degrees) and trabeculotomy (up to 360 degrees)

Treatment:

Device: Canaloplasty and trabeculotomy with the OMNI system.

Ab-interno canaloplasty (360 degrees) using the OMNI Surgical System

Active Comparator group

Description:

Canaloplasty alone (up to 360 degrees)

Treatment:

Device: Canaloplasty

Ab-interno implantation of iStent inject (2 microstents)

Active Comparator group

Description:

Implantation of trabecular micro bypass stents as per manufacturer's instructions.

Treatment:

Device: iStent inject